The efficacy and side effects of Osimertinib (Tagrisso)

Osimertinib (Tagrisso) is a targeted therapy drug mainly used to treat EGFR (epidermal growth factor receptor) mutation-positive non-small cell lung cancer (NSCLC), especially for those patients who are positive for the drug-resistant mutation T790M. Its efficacy and side effects are important factors for patients and doctors to consider when choosing a treatment option.

Efficacy:

1.Control tumor growth: Osimertinib (Tagressa) blocks the abnormal activation of the EGFR signaling pathway by inhibiting the activity of EGFR, thus inhibiting the growth and spread of tumor cells. This makes Osimertinib (Tagrisso) an effective treatment option that can help control the progression of lung cancer and extend patients' survival.

2.Prolonged progression-free survival (PFS): Clinical trial results show that Osimertinib (Tagressa) can significantly prolong the progression-free survival (PFS) of EGFR mutation-positive NSCLC patients. This means that during the patient's treatment with Osimertinib (Tagressa), the growth of the tumor was effectively inhibited and the progression of the disease was controlled.

3.Improved survival: Treatment with osimertinib (Tagrisso) is also associated with improved overall survival (OS). Some clinical studies have shown improved overall survival in patients treated with osimertinib (Tagressa) compared with traditional EGFR inhibitors.

Side effects:

1.Skin reaction: Skin rash is one of the common side effects of Osimertinib (Tagressa) treatment, which manifests as dry skin, itching, erythema, and scaling. Mild rashes usually do not require treatment, but topical or oral corticosteroids may be needed in severe cases.

2.Gastrointestinal reactions: Including diarrhea, nausea, vomiting, loss of appetite, etc. These reactions are usually mild to moderate and can be managed with dietary modifications, oral antidiarrheal medications, and other methods.

3.Fatigue: Many patients experience fatigue or weakness during treatment withosimertinib (Tagressa) . This may interfere with activities of daily living, but is usually not severe enough to require discontinuation of treatment.

4.Abnormal liver function: Some patients may develop abnormal liver function during treatment withosimertinib (Tagressa) , manifested by elevated transaminases, etc. Therefore, regular monitoring of liver function is very important.

5.Others: Other possible side effects include headache, cough, dry eyes, etc., but these are usually mild and have less impact on the patient's quality of life.

Although the side effects of Osimertinib (Tagressa) are usually mild to moderate, patients still need to pay close attention to the occurrence of any adverse reactions during treatment and report them to their doctor in a timely manner. The doctor will evaluate the patient's specific situation and may adjust the treatment plan or provide corresponding support measures. In summary, Osimertinib (Tagressa), as a targeted therapy, has significant efficacy in the treatment of EGFR mutation-positive advanced NSCLC patients, but patients and doctors need to pay attention to and manage possible side effects to ensure the best therapeutic effect.